filmarray
respiratori
panel
farp
fda
certifi
multiplex
pcr
detect
virus
bacteria
respons
upper
respiratori
tract
infect
thu
potenti
use
assess
agerel
preval
pathogen
observ
studi
retrospect
analyz
result
respiratori
sampl
process
yearperiod
novemb
novemb
farp
central
laboratori
hygeia
mitera
gener
hospit
athen
greec
order
agerel
distribut
follow
age
group
implement
year
old
among
respiratori
sampl
test
male
femal
patient
posit
neg
first
agegroup
sampl
reveal
human
rhinovirusenteroviru
hrv
adenoviru
adv
follow
respiratori
syncyti
viru
rsv
coronaviru
human
metapneumoviru
hmpv
parainfluenza
virus
piv
agegroup
adv
predomin
sampl
follow
hrv
rsv
coronaviru
type
influenza
hmpv
piv
agegroup
hrv
identifi
sampl
adv
influenza
hmpv
influenza
predomin
agegroup
sampl
remain
agegroup
hrv
commonest
isol
pathogen
follow
influenza
influenza
patient
seri
hrv
seem
prevail
agegroup
follow
adv
although
influenza
second
frequent
pathogen
isol
agegroup
moreov
increas
age
correspond
increas
possibl
neg
sampl
indic
filmarray
may
use
adolesc
abbrevi
adv
adenoviru
farp
filmarray
respiratori
panel
hcov
coronavirus
hmpv
human
metapneumoviru
hrsv
rsv
human
respiratori
syncyti
viru
hrv
human
rhinovirusenteroviru
piv
parainfluenza
viru
rs
respiratori
sampl
uri
upper
respiratori
tract
infect
upper
respiratori
tract
infect
uri
seriou
burden
healthcar
system
major
uri
viral
etiolog
definit
diagnosi
difficult
due
overlap
clinic
present
viral
bacteri
infect
variabl
sensit
lengthi
turnaround
time
viral
cultur
rapid
sensit
detect
respiratori
virus
essenti
earli
diagnosi
administr
appropri
antivir
therapi
well
effect
implement
infect
control
measur
filmarray
respiratori
panel
farp
assay
fulli
autom
multiplex
pcr
system
integr
nucleic
acid
extract
nest
amplif
detect
reaction
pouch
preload
reagent
requir
detect
virus
bacteria
requir
advanc
equip
expertis
molecular
diagnost
make
use
pointofcar
test
acut
respiratori
infect
valuabl
tool
assess
agerel
preval
respons
pathogen
order
investig
agerel
preval
respiratori
pathogen
retrospect
studi
result
sampl
process
yearperiod
novemb
novemb
farp
central
laboratori
hygeia
mitera
gener
hospit
athen
greec
among
respiratori
sampl
rs
test
male
femal
patient
median
age
patient
year
old
order
agerel
distribut
follow
age
group
implement
year
old
ethic
approv
andor
patient
consent
necessari
paper
report
primari
research
data
analyz
retrospect
collect
part
routin
diagnosi
nasopharyng
swab
specimen
collect
patient
symptomat
respiratori
tract
infect
process
farp
assay
detect
nucleic
acid
respiratori
virus
bacteria
includ
adenoviru
adv
coronavirus
hcov
human
respiratori
syncyti
viru
hrsv
rsv
human
metapneumoviru
hmpv
influenza
viru
influenza
b
viru
parainfluenza
virus
piv
includ
human
rhinovirusenteroviru
hrv
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
multiplex
pcr
extract
amplif
detect
step
take
place
separ
chamber
selfcontain
singleus
pouch
procedur
perform
accord
manufactur
instruct
chisquar
test
spss
statist
spss
chicago
il
usa
use
statist
analysi
p
consid
statist
signific
among
respiratori
sampl
test
posit
neg
total
number
pathogen
detect
larger
posit
sampl
due
frequent
multipl
isol
thu
pathogen
detect
hrv
adv
influenza
virus
b
usual
isol
pathogen
tabl
first
agegroup
sampl
reveal
hrv
adv
rsv
coronaviru
hmpv
piv
agegroup
adv
predomin
sampl
follow
hrv
rsv
coronaviru
type
influenza
b
hmpv
piv
agegroup
hrv
identifi
sampl
adv
influenza
b
hmpv
influenza
predomin
agegroup
sampl
remain
agegroup
hrv
commonest
isol
pathogen
follow
influenza
influenza
frequenc
pathogen
respect
agegroup
display
figur
statist
signific
differ
age
group
hrv
p
adv
p
influenza
p
rsv
p
p
coronaviru
p
base
figur
obviou
hrv
prevail
age
group
especi
group
among
adv
posit
sampl
signific
differ
age
group
case
case
p
rsv
posit
sampl
notic
age
year
old
regard
sampl
posit
influenza
b
predomin
influenza
age
group
due
influenza
b
case
major
case
influenza
notic
age
year
old
latter
also
true
hmpv
main
piv
type
detect
tabl
peak
incid
age
year
old
final
case
coronaviru
type
includ
detect
children
year
old
case
children
type
coronaviru
detect
singl
sampl
among
total
rs
reveal
multipl
isol
base
posit
sampl
multipl
pathogen
posit
rs
hrv
particip
multipl
isol
frequent
isol
pathogen
fig
second
frequent
observ
pathogen
piv
identifi
sampl
adv
identifi
sampl
follow
rsv
fig
remark
combin
hrvadv
commonli
observ
case
follow
hrvrsv
combin
tabl
regard
agerel
distribut
multipl
respiratori
pathogen
note
concern
age
year
old
combin
hrvadv
mainli
observ
age
group
tabl
also
remark
neg
sampl
mostli
encount
older
age
particular
age
group
tabl
spectrum
pathogen
detect
farp
irrespect
singl
multipl
identif
fig
respiratori
infect
common
caus
pediatr
morbid
vast
major
acut
uri
caus
virus
molecular
pointofcar
test
respiratori
virus
potenti
improv
detect
rate
respiratori
virus
improv
use
influenza
antivir
reduc
unnecessari
antibiot
use
howev
agerel
preval
identifi
upper
respiratori
pathogen
clearli
establish
studi
routin
clinic
applic
farp
indirectli
use
molecular
pointofcar
test
agestratif
respiratori
virus
detect
tertiari
hospit
greec
hrv
commonli
identifi
viru
almost
age
group
especi
group
increas
avail
multiplex
pcr
panel
allow
rapid
detect
hrv
provid
opportun
time
treatment
earli
recognit
outbreak
predomin
hrv
patient
seri
accord
previous
publish
data
includ
data
patient
age
hrv
previous
identifi
common
pathogen
detect
among
symptomat
young
children
pediatr
emerg
depart
major
requir
hospit
true
seri
case
symptomat
case
hospit
base
result
hrv
certainli
includ
differenti
diagnosi
uri
older
patient
case
adv
result
indic
age
group
seem
highest
risk
get
infect
adv
consid
frequent
respiratori
figur
neg
sampl
mostli
encount
older
age
peak
incid
age
group
tabl
agerel
frequenc
respiratori
combin
pattern
pathogen
among
children
infant
popul
highest
risk
studi
adv
refer
first
time
frequent
respons
pathogen
age
group
second
prioriti
among
identifi
pathogen
result
may
reflect
trend
increas
total
incid
higherag
peak
incid
adv
posit
case
rsv
regular
winter
visitor
highli
contagi
among
person
age
although
long
recogn
major
viral
pathogen
lower
respiratori
tract
infant
also
implic
sever
lung
diseas
adult
especi
elderli
confirm
studi
rsv
posit
sampl
notic
age
year
old
howev
notic
posit
case
occur
age
data
shown
belong
age
group
highlight
relev
viru
age
sampl
posit
influenza
b
underlin
total
preval
influenza
high
incid
influenza
age
year
old
prefer
influenza
b
incid
middl
age
influenza
b
import
caus
respiratori
ill
age
group
influenza
refer
common
etiolog
agent
especi
among
adult
true
case
except
age
group
howev
influenza
previous
consid
frequent
pathogen
commun
set
data
indic
appli
total
age
year
moreov
propos
highest
incid
hmpv
infect
among
children
seroposit
hmpv
approach
year
age
seri
although
hmpv
posit
case
identifi
age
also
case
age
year
old
underli
consider
number
hmpv
infect
diagnos
adult
elderli
final
piv
singlestrand
rna
virus
belong
paramyxoviru
famili
may
caus
uri
lower
respiratori
infect
infant
children
immunocompromis
individu
consid
almost
pivposit
sampl
pediatr
patient
younger
year
old
infant
month
age
found
posit
true
seri
repres
type
also
hcov
consid
import
respiratori
pathogen
especi
hospit
children
year
age
immunosuppress
patient
data
indic
although
case
belong
age
group
year
old
peak
incid
met
age
group
avail
refer
data
frequenc
respiratori
coinfect
vari
although
report
percentag
higher
result
studi
respiratori
sampl
children
year
age
farp
identifi
multipl
coinfect
differ
virus
coinfect
also
found
posit
respiratori
sampl
studi
respiratori
patient
multipl
pathogen
posit
respiratori
patient
almost
posit
sampl
appear
codetect
obviou
explan
signific
lower
frequenc
codetect
seri
patient
howev
predomin
hrv
singl
multipl
detect
accord
previous
publish
data
moreov
hrvadv
hrvrsv
combin
previous
mention
frequent
coinfect
pattern
interestingli
suggest
presenc
rsv
reduc
probabl
rhinoviru
infect
coinfect
occur
virus
caus
clinic
symptom
regard
agerel
distribut
multipl
pathogen
observ
patient
year
age
like
multipl
detect
almost
accord
elimin
previous
publish
data
nevertheless
tramuto
et
al
also
notic
patient
multipl
etiolog
adult
elderli
conclus
understand
viral
etiolog
agespecif
incid
uri
help
identifi
risk
group
probabl
inform
vaccin
deliveri
studi
hrv
predomin
almost
age
adv
age
group
influenza
second
age
final
remark
neg
sampl
mostli
attribut
older
age
peak
incid
age
group
confirm
age
patient
increas
posit
rate
pcr
decreas
proportion
find
need
explan
